Deciphering the Structural Biology of GFAP: Connotations of Its Potency in Presaging the Diagnosis for Traumatic Brain Injury and AD
Open Access
- 26 August 2025
- journal article
- review article
- Published by MDPI AG in Neurology International
- Vol. 17 (9) , 134
Abstract
In Alzheimer’s disease, accumulation of Aβ and tau aggregates in the limbic and cortical regions of the brain forms the pathological basis for the onset of memory loss and cognitive abnormalities. The neuronal desecration inflicted by these toxic pile-ups will rouse the onset of innate immune defense mechanisms including astrogliosis within the neuronal milieu. A potential ramification of astrogliosis is the overproduction and spillage of GFAP into the brain circulation. Execution of GFAP vital physiological functions rests upon the preservation of its filamentous structure as well as its cytoskeletal interactions. Any anomaly that hampers the structural integrity of GFAP will engender filament disassembly, cytoplasmic aggregation, and decreased solubility with the resultant deleterious consequences. The potency of GFAP as a reliable biomarker in the blood also rests on its ability to navigate the glymphatic excretory pathways and spill into the systemic circulation. Recent reports have suggested GFAP is a dependable marker for auguring subtle disease changes in traumatic brain injury (TBI) and AD. However, pathological anomalies such abnormal structural integrity, cleavage, impaired drainage pathways, and alternative isoforms will lessen its potency and thwarts its ability from becoming a full-fledged and stable biomarker for neurological diseases. Understanding the GFAP biology, including factors that influence its structural integrity and excretory pathways, will be crucial and this review underscores these sections in a succinct manner. Thorough comprehension of GFAP biology is the principal step in unearthing its potential as a powerful marker for auguring disease initiation, and progression in TBI and AD.Keywords
This publication has 179 references indexed in Scilit:
- Astroglial activation: Current concepts and future directionsAlzheimer's & Dementia, 2024
- The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Evaluation of Glial and Neuronal Blood Biomarkers Compared With Clinical Decision Rules in Assessing the Need for Computed Tomography in Patients With Mild Traumatic Brain InjuryJAMA Network Open, 2022
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumJAMA Neurology, 2021
- 2021 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2021
- Memantine for dementiaCochrane Database of Systematic Reviews, 2019
- Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain InjuryJAMA Neurology, 2016
- Dementia Risk After Traumatic Brain Injury vs Nonbrain TraumaJAMA Neurology, 2014
- Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanismGlia, 1996
- Neocortical Neurofibrillary Tangles Correlate With Dementia Severity in Alzheimer's DiseaseArchives of Neurology, 1995